Answers are grounded in this paper and cite their sources.
Although saracatinib was well tolerated in this patient population, there was no apparent impact of the drug in this double-blinded, placebo-controlled trial on OS, and Src inhibition alone may not be sufficient to suppress metastatic progression in osteosarcoma. There is a suggestion of potential clinical benefit as evidenced by longer PFS in patients randomized to saracatinib based on limited numbers of patients treated.
No takes yet. Share an insight, caveat, or question.
Baird et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: